Search

Your search keyword '"Bulabois, C"' showing total 111 results
Start Over Author "Bulabois, C"
111 results on '"Bulabois, C"'

1. Rapid response system for critically ill patients with haematological malignancies: A pre‐ and post‐intervention study.

Author

Mauz, N., Bouisse, M., Cahn, J. Y., Kaphan, E., Truche, A.‐S., Thiebaut‐Bertrand, A., Carré, M., Bulabois, C.‐E., Hamidfar‐Roy, R., Schwebel, C., Park, S., Labarere, J., and Terzi, N.

Abstract

Background: This study aimed to determine whether implementing a rapid response system (RRS) is associated with improved short‐term outcomes in critically ill patients with haematological malignancies. Methods: Our monocentric pre‐ versus post‐intervention study was conducted between January 2012 and April 2020. RRS was activated at early signs of haemodynamic or respiratory failure. The primary outcome was the reduction in Sequential Organ Failure Assessment (SOFA) score on Day 3 after intensive care unit (ICU) admission. Secondary outcomes included time to ICU admission and mortality. Results: A total of 209 patients with a median age of 59 years were enrolled (108 in the pre‐intervention period and 101 in the post‐intervention period). 22% of them had received an allogeneic transplant. The post‐intervention period was associated with a shorter time to ICU admission (195 vs. 390 min, p <.001), a more frequent favourable trend in SOFA score (57% vs. 42%, adjusted odds ratio, 2.02, 95% confidence interval, 1.09 to 3.76), no significant changes in ICU (22% vs. 26%, p =.48) and 1‐year (62% vs. 58%, p =.62) mortality rates. Conclusion: Detection of early organ failure and activation of an RRS was associated with faster ICU admission and lower SOFA scores on Day 3 of admission in critically ill patients with haematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

2. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author

Ruggeri, A, de Wreede, L, Muller, C, Crivello, P, Bonneville, E, Petersdorf, E, Socie, G, Dubois, V, Niittyvuopio, R, Perasaari, J, Yakoub-Agha, I, Cornelissen, J, Wieten, L, Gedde-Dahl, T, Forcade, E, Crawley, C, Marsh, S, Gandemer, V, Tholouli, E, Bulabois, C, Huynh, A, Choi, G, Deconinck, E, Itala-Remes, M, Lenhoff, S, Bengtsson, M, Johansson, J, van Gorkom, G, Hoogenboom, J, Vago, L, Rocha, V, Bonini, C, Chabannon, C, Fleischhauer, K, Clausen, J, Holter, W, Kalhs, P, Beguin, Y, Bron, D, Deeren, D, Lung, W, Kerre, T, Poire, X, Selleslag, D, Schroyens, W, Jindra, P, Mayer, J, Vydra, J, Zak, P, Nielsen, B, Sengeloev, H, Kaare, A, Partanen, A, Bay, J, Bertrand, Y, Blaise, D, Bourhis, J, Chevallier, P, Cluzeau, T, Damaj, G, Fegueux, N, Guyotat, D, Hunault-Berger, M, Labussiere-Wallet, H, Leleu, X, Lioure, B, Maury, S, Michel, G, Mohty, M, Rubio, M, Tilly, H, Turlure, P, Bethge, W, Casper, J, Einsele, H, Ganser, A, Kroger, N, Martin, S, Platzbecker, U, Reinhardt, C, Schafer-Eckart, K, Thurner, L, Valerius, T, Wulf, G, Karakasis, D, Spyridonidis, A, Hauser, P, Remenyi, P, Reykdal, S, Mousavi, A, Angelucci, E, Arcese, W, Benedetti, F, Bernasconi, P, Biondi, A, Bonifazi, F, Carella, A, Carluccio, P, Casini, M, Cavanna, L, Ciceri, F, Cimino, G, Corradini, P, Fanin, R, Galieni, P, Grillo, G, Iori, A, La Nasa, G, Locatelli, F, Marotta, G, Martino, M, Mazza, P, Mordini, N, Musso, M, Olivieri, A, Pavone, V, Pane, F, Petrini, M, Pioltelli, P, Rambaldi, A, Ruggeri, M, Saccardi, R, Santarone, S, Scime, R, Sica, S, Tarella, C, Velardi, A, Visani, G, Zecca, M, Tanase, A, Kulagin, A, Savchenko, V, Lopez, C, Amor, A, Lopez, J, Caballero, D, Duarte, R, Cascon, M, Porras, R, Perez-Simon, J, Rovira, M, Sanz, J, Carrete, J, Cammenga, J, Isaksson, C, Mielke, S, Chalandon, Y, Passweg, J, Schanz, U, Meijer, E, Kuball, J, Veelken, J, Apperley, J, Bloor, A, Byrne, J, Carpenter, B, Clark, A, Collin, M, Craddock, C, Gibson, B, Khan, A, Martin, M, Medd, P, Nicholson, E, Orchard, K, Patel, A, Peniket, A, Potter, V, Snowden, J, Wilson, K, Ruggeri A., de Wreede L. C., Muller C. R., Crivello P., Bonneville E. F., Petersdorf E. W., Socie G., Dubois V., Niittyvuopio R., Perasaari J., Yakoub-Agha I., Cornelissen J. J., Wieten L., Gedde-Dahl T., Forcade E., Crawley C. R., Marsh S. G. E., Gandemer V., Tholouli E., Bulabois C. -E., Huynh A., Choi G., Deconinck E., Itala-Remes M., Lenhoff S., Bengtsson M., Johansson J. -E., van Gorkom G., Hoogenboom J. D., Vago L., Rocha V., Bonini C., Chabannon C., Fleischhauer K., Clausen J., Holter W., Kalhs P., Beguin Y., Bron D., Deeren D., Lung W. K., Kerre T., Poire X., Selleslag D., Schroyens W., Jindra P., Mayer J., Vydra J., Zak P., Nielsen B., Sengeloev H., Kaare A., Partanen A., Bay J., Bertrand Y., Blaise D., Bourhis J. H., Chevallier P., Cluzeau T., Damaj G., Fegueux N., Guyotat D., Hunault-Berger M., Labussiere-Wallet H., Leleu X., Lioure B., Maury S., Michel G., Mohty M., Rubio M. T., Tilly H., Turlure P., Bethge W., Casper J., Einsele H., Ganser A., Kroger N., Martin S., Platzbecker U., Reinhardt C., Schafer-Eckart K., Thurner L., Valerius T., Wulf G. G., Karakasis D., Spyridonidis A., Hauser P., Remenyi P., Reykdal S., Mousavi A., Angelucci E., Arcese W., Benedetti F., Bernasconi P., Biondi A., Bonifazi F., Carella A. M., Carluccio P., Casini M., Cavanna L., Ciceri F., Cimino G., Corradini P., Fanin R., Galieni P., Grillo G., Iori A. P., La Nasa G., Locatelli F., Marotta G., Martino M., Mazza P., Mordini N., Musso M., Olivieri A., Pavone V., Pane F., Petrini M., Pioltelli P., Rambaldi A., Ruggeri M., Saccardi R., Santarone S., Scime R., Sica S., Tarella C., Velardi A., Visani G., Zecca M., Tanase A., Kulagin A., Savchenko V., Lopez C. A., Amor A. A., Lopez J. L. B., Caballero D., Duarte R., Cascon M. J. P., Porras R. P., Perez-Simon J. A., Rovira M., Sanz J., Carrete J. P. T., Cammenga J., Isaksson C., Mielke S., Chalandon Y., Passweg J., Schanz U., Meijer E., Kuball J., Veelken J. H., Apperley J., Bloor A., Byrne J., Carpenter B., Clark A., Collin M., Craddock C., Gibson B. E., Khan A., Martin M., Medd P., Nicholson E., Orchard K., Patel A., Peniket A., Potter V., Snowden J., Wilson K. M. O., Ruggeri, A, de Wreede, L, Muller, C, Crivello, P, Bonneville, E, Petersdorf, E, Socie, G, Dubois, V, Niittyvuopio, R, Perasaari, J, Yakoub-Agha, I, Cornelissen, J, Wieten, L, Gedde-Dahl, T, Forcade, E, Crawley, C, Marsh, S, Gandemer, V, Tholouli, E, Bulabois, C, Huynh, A, Choi, G, Deconinck, E, Itala-Remes, M, Lenhoff, S, Bengtsson, M, Johansson, J, van Gorkom, G, Hoogenboom, J, Vago, L, Rocha, V, Bonini, C, Chabannon, C, Fleischhauer, K, Clausen, J, Holter, W, Kalhs, P, Beguin, Y, Bron, D, Deeren, D, Lung, W, Kerre, T, Poire, X, Selleslag, D, Schroyens, W, Jindra, P, Mayer, J, Vydra, J, Zak, P, Nielsen, B, Sengeloev, H, Kaare, A, Partanen, A, Bay, J, Bertrand, Y, Blaise, D, Bourhis, J, Chevallier, P, Cluzeau, T, Damaj, G, Fegueux, N, Guyotat, D, Hunault-Berger, M, Labussiere-Wallet, H, Leleu, X, Lioure, B, Maury, S, Michel, G, Mohty, M, Rubio, M, Tilly, H, Turlure, P, Bethge, W, Casper, J, Einsele, H, Ganser, A, Kroger, N, Martin, S, Platzbecker, U, Reinhardt, C, Schafer-Eckart, K, Thurner, L, Valerius, T, Wulf, G, Karakasis, D, Spyridonidis, A, Hauser, P, Remenyi, P, Reykdal, S, Mousavi, A, Angelucci, E, Arcese, W, Benedetti, F, Bernasconi, P, Biondi, A, Bonifazi, F, Carella, A, Carluccio, P, Casini, M, Cavanna, L, Ciceri, F, Cimino, G, Corradini, P, Fanin, R, Galieni, P, Grillo, G, Iori, A, La Nasa, G, Locatelli, F, Marotta, G, Martino, M, Mazza, P, Mordini, N, Musso, M, Olivieri, A, Pavone, V, Pane, F, Petrini, M, Pioltelli, P, Rambaldi, A, Ruggeri, M, Saccardi, R, Santarone, S, Scime, R, Sica, S, Tarella, C, Velardi, A, Visani, G, Zecca, M, Tanase, A, Kulagin, A, Savchenko, V, Lopez, C, Amor, A, Lopez, J, Caballero, D, Duarte, R, Cascon, M, Porras, R, Perez-Simon, J, Rovira, M, Sanz, J, Carrete, J, Cammenga, J, Isaksson, C, Mielke, S, Chalandon, Y, Passweg, J, Schanz, U, Meijer, E, Kuball, J, Veelken, J, Apperley, J, Bloor, A, Byrne, J, Carpenter, B, Clark, A, Collin, M, Craddock, C, Gibson, B, Khan, A, Martin, M, Medd, P, Nicholson, E, Orchard, K, Patel, A, Peniket, A, Potter, V, Snowden, J, Wilson, K, Ruggeri A., de Wreede L. C., Muller C. R., Crivello P., Bonneville E. F., Petersdorf E. W., Socie G., Dubois V., Niittyvuopio R., Perasaari J., Yakoub-Agha I., Cornelissen J. J., Wieten L., Gedde-Dahl T., Forcade E., Crawley C. R., Marsh S. G. E., Gandemer V., Tholouli E., Bulabois C. -E., Huynh A., Choi G., Deconinck E., Itala-Remes M., Lenhoff S., Bengtsson M., Johansson J. -E., van Gorkom G., Hoogenboom J. D., Vago L., Rocha V., Bonini C., Chabannon C., Fleischhauer K., Clausen J., Holter W., Kalhs P., Beguin Y., Bron D., Deeren D., Lung W. K., Kerre T., Poire X., Selleslag D., Schroyens W., Jindra P., Mayer J., Vydra J., Zak P., Nielsen B., Sengeloev H., Kaare A., Partanen A., Bay J., Bertrand Y., Blaise D., Bourhis J. H., Chevallier P., Cluzeau T., Damaj G., Fegueux N., Guyotat D., Hunault-Berger M., Labussiere-Wallet H., Leleu X., Lioure B., Maury S., Michel G., Mohty M., Rubio M. T., Tilly H., Turlure P., Bethge W., Casper J., Einsele H., Ganser A., Kroger N., Martin S., Platzbecker U., Reinhardt C., Schafer-Eckart K., Thurner L., Valerius T., Wulf G. G., Karakasis D., Spyridonidis A., Hauser P., Remenyi P., Reykdal S., Mousavi A., Angelucci E., Arcese W., Benedetti F., Bernasconi P., Biondi A., Bonifazi F., Carella A. M., Carluccio P., Casini M., Cavanna L., Ciceri F., Cimino G., Corradini P., Fanin R., Galieni P., Grillo G., Iori A. P., La Nasa G., Locatelli F., Marotta G., Martino M., Mazza P., Mordini N., Musso M., Olivieri A., Pavone V., Pane F., Petrini M., Pioltelli P., Rambaldi A., Ruggeri M., Saccardi R., Santarone S., Scime R., Sica S., Tarella C., Velardi A., Visani G., Zecca M., Tanase A., Kulagin A., Savchenko V., Lopez C. A., Amor A. A., Lopez J. L. B., Caballero D., Duarte R., Cascon M. J. P., Porras R. P., Perez-Simon J. A., Rovira M., Sanz J., Carrete J. P. T., Cammenga J., Isaksson C., Mielke S., Chalandon Y., Passweg J., Schanz U., Meijer E., Kuball J., Veelken J. H., Apperley J., Bloor A., Byrne J., Carpenter B., Clark A., Collin M., Craddock C., Gibson B. E., Khan A., Martin M., Medd P., Nicholson E., Orchard K., Patel A., Peniket A., Potter V., Snowden J., and Wilson K. M. O.

Published
2023

3. Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation

Author

Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., Locatelli F. (ORCID:0000-0002-7976-3654), Ruggeri, A., de Wreede, L. C., Muller, C. R., Crivello, P., Bonneville, E. F., Petersdorf, E. W., Socie, G., Dubois, V., Niittyvuopio, R., Perasaari, J., Yakoub-Agha, I., Cornelissen, J. J., Wieten, L., Gedde-Dahl, T., Forcade, E., Crawley, C. R., Marsh, S. G. E., Gandemer, V., Tholouli, E., Bulabois, C. -E., Huynh, A., Choi, G., Deconinck, E., Itala-Remes, M., Lenhoff, S., Bengtsson, M., Johansson, J. -E., van Gorkom, G., Hoogenboom, J. D., Vago, L., Rocha, V., Bonini, C., Chabannon, C., Fleischhauer, K., Clausen, J., Holter, W., Kalhs, P., Beguin, Y., Bron, D., Deeren, D., Lung, W. K., Kerre, T., Poire, X., Selleslag, D., Schroyens, W., Jindra, P., Mayer, J., Vydra, J., Zak, P., Nielsen, B., Sengeloev, H., Kaare, A., Partanen, A., Bay, J., Bertrand, Y., Blaise, D., Bourhis, J. H., Chevallier, P., Cluzeau, T., Damaj, G., Fegueux, N., Guyotat, D., Hunault-Berger, M., Labussiere-Wallet, H., Leleu, X., Lioure, B., Maury, S., Michel, G., Mohty, M., Rubio, M. T., Tilly, H., Turlure, P., Bethge, W., Casper, J., Einsele, H., Ganser, A., Kroger, N., Martin, S., Platzbecker, U., Reinhardt, C., Schafer-Eckart, K., Thurner, L., Valerius, T., Wulf, G. G., Karakasis, D., Spyridonidis, A., Hauser, P., Remenyi, P., Reykdal, S., Mousavi, A., Angelucci, E., Arcese, W., Benedetti, F., Bernasconi, P., Biondi, A., Bonifazi, F., Carella, A. M., Carluccio, P., Casini, M., Cavanna, L., Ciceri, F., Cimino, G., Corradini, P., Fanin, R., Galieni, P., Grillo, G., Iori, A. P., La Nasa, G., Locatelli, Franco, Marotta, G., Martino, M., Mazza, P., Mordini, N., Musso, M., Olivieri, A., Pavone, V., Pane, F., Petrini, M., Pioltelli, P., Rambaldi, A., Ruggeri, M., Saccardi, R., Santarone, S., Scime, R., Sica, S., Tarella, C., Velardi, A., Visani, G., Zecca, M., Tanase, A., Kulagin, A., Savchenko, V., Lopez, C. A., Amor, A. A., Lopez, J. L. B., Caballero, D., Duarte, R., Cascon, M. J. P., Porras, R. P., Perez-Simon, J. A., Rovira, M., Sanz, J., Carrete, J. P. T., Cammenga, J., Isaksson, C., Mielke, S., Chalandon, Y., Passweg, J., Schanz, U., Meijer, E., Kuball, J., Veelken, J. H., Apperley, J., Bloor, A., Byrne, J., Carpenter, B., Clark, A., Collin, M., Craddock, C., Gibson, B. E., Khan, A., Martin, M., Medd, P., Nicholson, E., Orchard, K., Patel, A., Peniket, A., Potter, V., Snowden, J., Wilson, K. M. O., and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

NO ABSTRACT

Published
2023

4. Efficacy of haematopoietic stem cell boost as a rescue for poor graft function after haematopoietic stem cell transplantation: A multicentre retrospective study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy ( SFGM‐TC )

Author

Gaffet, M., primary, Wiedemann, A., additional, Dalle, J.‐H., additional, Bilger, K., additional, Forcade, E., additional, Robin, M., additional, Cornillon, J., additional, Labussière‐Wallet, H., additional, Ceballos, P., additional, Bulabois, C.‐E., additional, Loschi, M., additional, Orvain, C., additional, Rubio, M. T., additional, Neven, B., additional, Pagliuca, S., additional, and Pochon, C., additional

Published
2023
Full Text
View/download PDF

5. Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord

Author

Nguyen, S, Achour, A, Souchet, L, Vigouroux, S, Chevallier, P, Furst, S, Sirvent, A, Bay, J-O, Socié, G, Ceballos, P, Huynh, A, Cornillon, J, Francois, S, Legrand, F, Yakoub-Agha, I, Michel, G, Maillard, N, Margueritte, G, Maury, S, Uzunov, M, Bulabois, C-E, Michallet, M, Clement, L, Dauriac, C, Bilger, K, Lejeune, J, Béziat, V, Rocha, V, Rio, B, Chevret, S, and Vieillard, V

Published
2017
Full Text
View/download PDF

6. Late relapse after hematopoietic stem cell transplantation for acute leukemia: a retrospective study by SFGM-TC

Author

Kaphan, E., primary, Bettega, F., additional, Forcade, E., additional, Labussière-Wallet, H., additional, Fegueux, N., additional, Robin, M., additional, De Latour, R. Peffault, additional, Huynh, A., additional, Lapierre, L., additional, Berceanu, A., additional, Marcais, A., additional, Debureaux, P.E., additional, Vanlangendonck, N., additional, Bulabois, C.-E., additional, Magro, L., additional, Daniel, A., additional, Galtier, J., additional, Lioure, B., additional, Chevallier, P., additional, Antier, C., additional, Loschi, M., additional, Guillerm, G., additional, Mear, J.B., additional, Chantepie, S., additional, Cornillon, J., additional, Rey, G., additional, Poire, X., additional, Bazarbachi, A., additional, Rubio, M.T., additional, Contentin, N., additional, Orvain, C., additional, Dulery, R., additional, Bay, J.O., additional, Croizier, C., additional, Beguin, Y., additional, Charbonnier, A., additional, Skrzypczak, C., additional, Desmier, D., additional, Villate, A., additional, Carré, M., additional, and Thiebaut-Bertrand, A., additional

Published
2023
Full Text
View/download PDF

7. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author

Mamez, A-C, Lévy, V, Chevallier, P, Blaise, D, Vigouroux, S, Xhaard, A, Fegueux, N, Contentin, N, Beguin, Y, Ifrah, N, Bulabois, C-E, Suarez, F, Yakoub-Agha, I, Turlure, P, Deconink, E, Lamy, T, Cahn, J Y, Huynh, A, Maury, S, Fornecker, L M, Ouzegdouh, M, Bay, J-O, Guillerm, G, Maillard, N, Michallet, M, Malfuson, J-V, Bourhis, J-H, Rialland, F, Oumedaly, R, Jubert, C, Leblond, V, Boubaya, M, Mohty, M, and Nguyen, S

Published
2016
Full Text
View/download PDF

8. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire

Author

Le Bourgeois, A., Labopin, M., Blaise, D., Ceballos, P., Vigouroux, S., Peffault de Latour, R., Marçais, A., Bulabois, C. E., Bay, J. O., Chantepie, S., Deconinck, E., Daguindau, E., Contentin, N., Yakoub-Agha, I., Cornillon, J., Mercier, M., Turlure, P., Charbonnier, A., Rorhlich, P. S., N’Guyen, S., Maillard, N., Marchand, T., Mohty, M., and Chevallier, P.

Published
2017
Full Text
View/download PDF

9. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS

Author

Harbi, S., primary, Boher, J.-M., additional, Forcade, E., additional, Chevallier, P., additional, Peffault De Latour, R., additional, Malard, F., additional, Francois, S., additional, Charbonnier, A., additional, Hermet, E., additional, Bulabois, C. E., additional, Huynh, A., additional, Berceanu, A., additional, Cluzeau, T., additional, Rubio, M. T., additional, Furst, S., additional, devillier, R., additional, Mohty, M., additional, and Blaise, D., additional

Published
2022
Full Text
View/download PDF

11. Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study

Author

Largeaud, Laetitia, Cornillet-Lefebvre, Pascale, Hamel, Jean-François, Dumas, Pierre-Yves, Prade, Naïs, Dufrechou, Stéphanie, Plenecassagnes, Julien, Luquet, Isabelle, Blanchet, Odile, Banos, Anne, Béné, Marie, Bernard, Marc, Bertoli, Sarah, Bonmati, Caroline, Fornecker, Luc Matthieu, Guièze, Romain, Haddaoui, Lamya, Hunault, Mathilde, Ianotto, Jean Christophe, Jourdan, Eric, Ojeda, Mario, Peterlin, Pierre, Vey, Norbert, Zerazhi, Hacene, Yosr, Hicheri, Mineur, Ariane, Cahn, Jean-Yves, Ifrah, Norbert, Récher, Christian, Pigneux, Arnaud, Delabesse, Eric, Marolleau, J.-P., Aleme, A., Orsini-Piocelle, F., Cadoux, N., Marie, C., Al Jijakli, A., Lepeu, G., Beyrne, M., Labarrere, S., Deconinck, E., Peria, M., El Yamani, A., Kadiri, O., Choufi, B., Brument, M., Leguay, T., Berthou, C., Guillerm, G., Drugmanne, G., Tournilhac, O., Roy, G., Audhuy, B., Camara, S., Caillot, D., Grandjean, M., Bulabois, C.-E., Fief, B., Ladraa, C., Dorvaux, V., Hagopian, M., Fegueux, N., Fenoll, C., Sabadash, V., Haby, C., Witz, F., Lhuire, M., Delaunay, J., Airiau, L., Mannone, L., Touitou, I., Umuhire, D., Alexis, M., Michel, O., Dreyfus, F., Bouscary, D., Cheung, A., Sanhes, L., Touhami, F., Ribas, E., Puyade, M., Gallego-Hernanz, M.-P., Hugon, N., Himberlin, C., Maggi, L., Lamy, T., Testu, A., Tavernier, E., Marchand, S., Lioure, B., Kravanja, C., Benboubker, L., Nollet, D., Attal, M., Sarry, A., Lhermitte, A., Yrica, G., Schwartz, D., Le Montagner, N., Auvray, L., Delepine, R., Fayault, A., Centre de Recherches en Cancérologie de Toulouse (CRCT), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Service d'Hématologie Biologique [Hôpital Robert Debré, Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), CHU Bordeaux, Service d'Hématologie Clinique et Thérapie Cellulaire, F-33000 Bordeaux, France., Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Claudius Regaud, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier de la Côte Basque (CHCB), Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Hématologie Clinique (BREST - Hémato Clinique), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Université de Montpellier (UM), Service d’Hématologie [Institut Paoli Calmettes, Marseille], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), and Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, NPM1, Karyotype, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk profile, law.invention, 03 medical and health sciences, Cytogenetics, 0302 clinical medicine, Randomized controlled trial, law, Lomustine, Internal medicine, medicine, Biomarkers, Tumor, Idarubicin, Humans, Antineoplastic Agents, Alkylating, ComputingMilieux_MISCELLANEOUS, Chromosome Aberrations, business.industry, Cytarabine, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, Prognosis, 3. Good health, Leukemia, Myeloid, Acute, 030104 developmental biology, 030220 oncology & carcinogenesis, Karyotyping, Mutation, Female, business, Nucleophosmin, medicine.drug
Abstract

International audience; We previously reported the benefit of lomustine addition to conventional chemotherapy in older acute myeloid leukemias with nonadverse chromosomal aberrations in the LAM-SA 2007 randomized clinical trial (NCT00590837). A molecular analysis of 52 genes performed in 330 patients included in this trial, 163 patients being treated with lomustine in combination with idarubicin and cytarabine and 167 without lomustine, identified 1088 mutations with an average of 3.3 mutations per patient. NPM1, FLT3, and DNMT3A were the most frequently mutated genes. A putative therapeutic target was identified in 178 patients (54%). Among five molecular classifications analyzed, the ELN2017 risk classification has the stronger association with the clinical evolution. Patients not treated with lomustine have an expected survival prognosis in agreement with this classification regarding the overall and event-free survivals. In strong contrast, lomustine erased the ELN2017 classification prognosis. The benefit of lomustine in nonadverse chromosomal aberrations was restricted to patients with RUNX1, ASXL1, TP53, and FLT3-ITDhigh/NPM1WT mutations in contrast to the intermediate and favorable ELN2017 patients. This post-hoc analysis identified a subgroup of fit elderly AML patients with intermediate cytogenetics and molecular markers who may benefit from lomustine addition to intensive chemotherapy.

Published
2021
Full Text
View/download PDF

12. Tandem versus single autologous peripheral blood stem cell transplantation as post-remission therapy in adult acute myeloid leukemia patients under 60 in first complete remission: results of the multicenter prospective phase III GOELAMS LAM-2001 trial

Author

Chevallier, P, Fornecker, L, Lioure, B, Béné, M C, Pigneux, A, Recher, C, Witz, B, Fegueux, N, Bulabois, C-E, Daliphard, S, Bouscary, D, Vey, N, Delain, M, Bay, J-O, Turlure, P, Bernard, M, Himberlin, C, Luquet, I, Ifrah, N, and Harousseau, J-L

Published
2010
Full Text
View/download PDF

13. EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT:A SFGM-TC STUDY ON 64 PATIENTS: PH-O112

Author

Mamez, A.-C., Levy, V., Chevallier, P., Vigouroux, S., Xhaard, A., Contentin, N., Mohty, M., Yakoub-Agha, I., Bulabois, C. E., Deconink, E., Lamy, T., huynh, A., Fegueux, N., Turlure, P., Maury, S., Beguin, Y., Bourhis, J.-H., Bilger, K., Bay, J.-O., Guillerm, G., Suarez, F., Maillard, N., Rialland, F., Jubert, C., and Quoc, Nguyen S.

Published
2014

16. Therapeutic management of patients relapsing after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome: a large-scale study on behalf of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC): O154

Author

Guièze, R., Damaj, G., Robin, M., Mohty, M., Michallet, M., Tabrizi, R., Beguin, Y., Blaise, D., Roosweil, D., Bulabois, C.-E., Legrand, F., Huynh, A., Cornillon, J., Contentin, N., Suarez, F., Lioure, B., Maillard, N., Clément, L., Guillerm, G., Rubio, M.-T., Garnier, F., and Yakoub-Agha, I.

Published
2013

18. Reduce-intensity conditioning regimen prior to unrelated cord blood transplantation in patients with acute myeloid leukaemia: a prospective phase II multicentric trial of the Société Française de Greffe de Moelle et Thérapie Cellulaire and Eurocord: O159

Author

Rio, B., Chevret, S., Vigouroux, S., Chevallier, P., Furst, S., Sirvent, A., Bay, J. O., Socie, G., Ceballos, P., Huynh, A., Cornillon, J., François, S., Legrand, F., Yakoub-Agha, I., Gerard, M., Maillard, N., Margueritte, G., Maury, S., Uzunov, M., Bulabois, C. E., Michallet, M., Clement, L., Dauriac, C., Bilger, K., Simon, T., Gluckman, E., pied, Mil N., and Rocha, V.

Published
2011

20. Encouraging results of unrelated cord blood transplantation after homogenous reduced-intensity conditioning in adults with hematological malignancy: impact of HLA disparities on outcomes. A French multicentre study on behalf of the SFGM-TC and Eurocord: O107

Author

Rio, B., Furst, A., Renaud, M., Legrand, F., Tabrizi, R., Uzunov, M., Lapusan, S., Blaise, D., Deconinck, E., Bourhis, J. H., Fouillard, L., Bulabois, C., Ceballos, P., Maury, S., Chevalier, P., Mohty, M., François, S., Huynh, A., Michallet, M., Sirvent, A., Dhedin, N., Contentin, N., Buzyn, A., Guyotat, D., Fagot, T., Yakoub-Agha, I., Gluckman, E., Ionescu, I., Milpied, N., and Rocha, V.

Published
2009

21. HLA disparity, cell dose and age as risk factors for DFS in cord blood transplantation after non-myeloablative conditioning in 112 adults with haematological malignancies. A French multicentre study of the SFGM-TC and Eurocord

Author

Rio, B., Blaise, D., Renaud, M., Uzunov, M., Bourhis, J. h., Ceballos, P., Maury, S., Bulabois, C., Fouillard, L., Deconinck, E., Dhedin, N., Sirvent, A., Michallet, M., Contentin, N., Huynh, A., Buzyn, A., François, S., Tabrizi, R., Yakoub-Agha, I., Chevalier, P., De Revel, T., Lapusan, S., Garnier, F., Boudjedir, K., Gluckman, E., and Rocha, V.

Published
2008

22. PS993 DE NOVO ADULT ACUTE MYELOID LEUKEMIA PATIENTS DISPLAY AT DIAGNOSIS FUNCTIONAL DEREGULATION OF REDOX BALANCE CORRELATED WITH MOLECULAR SUBTYPES AND OVERALL SURVIVAL

Author

Mondet, J., primary, Presti, C. Lo, additional, Garrel, C., additional, Skaare, K., additional, Mariette, C., additional, Carras, S., additional, Carré, M., additional, Park, S., additional, Bulabois, C.-E., additional, Molina, L., additional, Gressin, R., additional, Thiebaut, A., additional, Courby, S., additional, Socoro-Yuste, N., additional, Faure, P., additional, Leer-Florin, A. Mc, additional, Cahn, J.-Y., additional, and Mossuz, P., additional

Published
2019
Full Text
View/download PDF

25. REDUCED INTENSITY (FB2) VS REDUCED TOXICITY MYELOABLATIVE (FB3-4) FLUDARABINE/BUSULFAN-BASED CONDITIONING REGIMENS FOR NON-HODGKIN LYMPHOMA (NHL) ALLOGRAFTED PATIENTS

Author

Le Bourgeois, A., primary, Labopin, M., additional, Blaise, D., additional, Ceballos, P., additional, Vigouroux, S., additional, Peffault De Latour, R., additional, Suarez, F., additional, Bulabois, C., additional, Bay, J., additional, Chantepie, S., additional, Deconinck, E., additional, Daguindau, E., additional, Contentin, N., additional, Yakoub-Agha, I., additional, Cornillon, J., additional, Francois, S., additional, Turlure, P., additional, Charbonnier, A., additional, Rohrlich, P., additional, N'Guyen, S., additional, Maillard, N., additional, Marchand, T., additional, Mohty, M., additional, and Chevalllier, P., additional

Published
2017
Full Text
View/download PDF

28. Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)

Author

Mamez, A-C, primary, Lévy, V, additional, Chevallier, P, additional, Blaise, D, additional, Vigouroux, S, additional, Xhaard, A, additional, Fegueux, N, additional, Contentin, N, additional, Beguin, Y, additional, Ifrah, N, additional, Bulabois, C-E, additional, Suarez, F, additional, Yakoub-Agha, I, additional, Turlure, P, additional, Deconink, E, additional, Lamy, T, additional, Cahn, J Y, additional, Huynh, A, additional, Maury, S, additional, Fornecker, L M, additional, Ouzegdouh, M, additional, Bay, J-O, additional, Guillerm, G, additional, Maillard, N, additional, Michallet, M, additional, Malfuson, J-V, additional, Bourhis, J-H, additional, Rialland, F, additional, Oumedaly, R, additional, Jubert, C, additional, Leblond, V, additional, Boubaya, M, additional, Mohty, M, additional, and Nguyen, S, additional

Published
2015
Full Text
View/download PDF

29. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation

Author

Rubio, M. T., primary, Labopin, M., additional, Blaise, D., additional, Socie, G., additional, Contreras, R. R., additional, Chevallier, P., additional, Sanz, M. A., additional, Vigouroux, S., additional, Huynh, A., additional, Shimoni, A., additional, Bulabois, C.-E., additional, Caminos, N., additional, Lopez-Corral, L., additional, Nagler, A., additional, and Mohty, M., additional

Published
2015
Full Text
View/download PDF

30. Endogenous megakaryocytic colonies underline association between megakaryocytes and calreticulin mutations in essential thrombocythemia

Author

Mondet, J., primary, Park, J.-H., additional, Menard, A., additional, Marzac, C., additional, Carillo, S., additional, Pourcelot, E., additional, Girodon, F., additional, Cabagnols, X., additional, Lode, L., additional, Socoro, N., additional, Chauvet, M., additional, Bulabois, C.-E., additional, Cony-Makhoul, P., additional, Corm, S., additional, Cahn, J.-Y., additional, and Mossuz, P., additional

Published
2015
Full Text
View/download PDF

31. Impact des anticorps anti-HLA sur le devenir de l’allogreffe de cellules souches hématopoïétiques : un rapport par la SFGM-TC

Author

Loiseau, P., primary, Dubois, V., additional, Bonafoux, B., additional, Bulabois, C.-E., additional, Coiteux, V., additional, Eliaou, J.-F., additional, Labaky, M., additional, Michallet, M., additional, Renac, V., additional, Delbos, F., additional, Kennel, A., additional, Detrait, M., additional, Devys, A., additional, Galambrun, C., additional, and Yakoub-Agha, I., additional

Published
2014
Full Text
View/download PDF

32. Greffes de cellules souches hématopoïétiques à partir d’un donneur haplo-identique : recommandations de la SFGM-TC (première partie)

Author

Blaise, D., primary, Nguyen, S., additional, Bay, J.-O., additional, Chevallier, P., additional, Contentin, N., additional, Dhédin, N., additional, Duléry, R., additional, Eliaou, J.-F., additional, Rubio, M.-T., additional, Suarez, F., additional, Bulabois, C.-E., additional, Cornillon, J., additional, Huynh, A., additional, Magro, L., additional, Michallet, M., additional, Paillard, C., additional, Turlure, P., additional, and Yakoub-Agha, I., additional

Published
2014
Full Text
View/download PDF

33. Greffes de cellules souches hématopoïétiques à partir d’un donneur haploidentique : recommandations de la SFGM-TC (deuxième partie)

Author

Nguyen, S., primary, Blaise, D., additional, Bay, J.-O., additional, Chevallier, P., additional, Contentin, N., additional, Dhédin, N., additional, Duléry, R., additional, Eliaou, J.-F., additional, Rubio, M.-T., additional, Suarez, F., additional, Bulabois, C.-E., additional, Cornillon, J., additional, Huynh, A., additional, Magro, L., additional, Michallet, M., additional, Paillard, C., additional, Turlure, P., additional, and Yakoub-Agha, I., additional

Published
2014
Full Text
View/download PDF

34. Prise en charge d’une réactivation/infection à CMV chez l’allogreffé et prise en charge de la réactivation EBV/syndrome lymphoproflifératif à EBV chez l’allogreffé de cellules souches hématopoïétiques

Author

Bay, J.-O., primary, Peffault de Latour, R., additional, Bruno, B., additional, Coiteux, V., additional, Guillaume, T., additional, Hicheri, Y., additional, Paillard, C., additional, Suarez, F., additional, Turlure, P., additional, Alain, S., additional, Bulabois, C.-E., additional, Socié, G., additional, Bauters, F., additional, and Yakoub-Agha, I., additional

Published
2013
Full Text
View/download PDF

36. Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenstrom's macroglobulinemia. Results of a retrospective analysis of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire

Author

Garnier, A., primary, Robin, M., additional, Larosa, F., additional, Golmard, J.-L., additional, Le Gouill, S., additional, Coiteux, V., additional, Tabrizi, R., additional, Bulabois, C.-E., additional, Cacheux, V., additional, Kuentz, M., additional, Dreyfus, B., additional, Dreger, P., additional, Rio, B., additional, Moles-Moreau, M.-P., additional, Bilger, K., additional, Bay, J.-O., additional, Leblond, V., additional, Blaise, D., additional, Tournilhac, O., additional, and Dhedin, N., additional

Published
2010
Full Text
View/download PDF

37. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the Société Française de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

Author

Mohty, M, primary, Attal, M, additional, Marit, G, additional, Bulabois, C E, additional, Garban, F, additional, Gratecos, N, additional, Rio, B, additional, Vernant, J P, additional, Sotto, J J, additional, Cahn, J Y, additional, Blaise, D, additional, Jouet, J P, additional, Facon, T, additional, and Yakoub-Agha, I, additional

Published
2004
Full Text
View/download PDF

38. Thalidomide salvage therapy following allogeneic stem cell transplantation for multiple myeloma: a retrospective study from the Intergroupe Francophone du Myélome (IFM) and the SociétéFrançaise de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

Author

Mohty, M, Attal, M, Marit, G, Bulabois, C. E., Garban, F., Gratecos, N., Rio, B., Vernant, J. P., Sotto, J. J., Cahn, J. Y., Blaise, D., Jouet, J. P., Facon, T., and Yakoub-Agha, I.

Subjects
THALIDOMIDE, TOXICITY testing, MULTIPLE myeloma, STEM cell transplantation, GRAFT versus host disease, BONE marrow transplantation
Abstract

Summary:Thalidomide is effective in multiple myeloma (MM), even in patients who have relapsed after high-dose therapy. A potent graft-versus-myeloma (GVM) effect can be induced against MM after allogeneic stem cell transplantation (allo-SCT). In all, 31 MM patients received thalidomide as a salvage therapy after progression following allo-SCT. The median maximum daily dose of thalidomide was 200?mg (range, 50-600). Thalidomide had to be discontinued in six patients (19%) because of toxicity. In all, nine patients (29%; 95%CI, 13-45) achieved an objective response with thalidomide therapy (six partial and three very good partial responses, VGPR). Five patients developed graft-versus-host disease (GVHD) after thalidomide therapy, including the three patients achieving a VGPR. These data demonstrate that thalidomide is potentially effective in MM patients failing allo-SCT.Bone Marrow Transplantation (2005) 35, 165-169. doi:10.1038/sj.bmt.1704756 Published online 8 November 2004 [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

39. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience.

Author

Milpied, N, Gaillard, F, Moreau, P, Mahé, B, Souchet, J, Rapp, M J, Bulabois, C E, Morineau, N, and Harousseau, J L

Subjects
STEM cell transplantation, LYMPHOMAS
Abstract

From 1991 to 1997 18 consecutive patients with well-defined mantle cell lymphoma (MCL) underwent high-dose therapy with unpurged autologous (17 patients) or allogeneic (one patient) stem cell transplantation. Tissue sections were reviewed for morphology, immunophenotype, cyclin D1 and P53 expression as well as proliferation index (PI). Median age of patients was 47 years (range 40–60). Sixteen had stage IV disease with bone marrow involvement in 12 and performance status was 1 in 12 patients. At the time of high-dose therapy 10 patients were in first partial response (PR), one was in second complete remission (CR), four were in second PR and three were refractory to conventional anthracycline-containing chemotherapy. The conditioning regimen consisted of TBI plus chemotherapy in 13 patients and chemotherapy only (BEAM) in five patients. No treatment-related deaths were observed. With a median follow-up of 36 months (range 13–80) after transplant, disease-free survival (DFS) and overall survival (OS) are estimated to be 48 and 80% at 4 years, respectively. Significantly better results are achieved for patients transplanted after a TBI containing regimen with a 4 year OS and DFS estimated at 89 and 71%, respectively compared to 60 and 0% respectively for patients who were conditioned without TBI (P = 0.07 for OS and P < 0.0001 for dfs). there is a trend towards better dfs when the transplant is performed in pr1 (4 year dfs: 80% with eight patients out of 10 in continuous cr 13 to 80 months, median 36 months after transplant) compared to more advanced stages (4 year dfs: 18% with only three patients out of eight in continuous cr 16, 17 and 58 months after transplant). blastic histology and p53 overexpression are also associated with a trend towards a worst prognosis. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

40. HLA disparity, cell dose and age as risk factors for DFS in cord blood transplantation after non-myeloablative conditioning in 112 adults with haematological malignancies. A French multicentre study of the SFGM-TC and Eurocord

Author

Rio, B., Blaise, D., Renaud, M., Uzunov, M., Bourhis, J. H., Ceballos, P., Maury, S., Bulabois, C., Fouillard, L., Deconinck, E., Dhedin, N., Sirvent, A., Michallet, M., Contentin, N., Huynh, A., Buzyn, A., Francois, S., Tabrizi, R., Ibrahim Yakoub-Agha, Chevalier, P., Revel, T., Lapusan, S., Garnier, F., Boudjedir, K., Gluckman, E., and Rocha, V.

41. HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia

Author

Baron, F., Labopin, M., Tischer, J., Ciceri, F., Raiola, A. M., Blaise, D., Sica, S., Vydra, J., Fanin, R., Diez-Martin, J. L., Bulabois, C. E., Stolzel, F., Busca, A., Jindra, P., Koc, Y., Chevallier, P., Forcade, E., Rosler, W., Passweg, J., Alexander Kulagin, Carella, A. M., Simand, C., Bazarbachi, A., Pioltelli, P., Nagler, A., and Mohty, M.

42. Encouraging results of unrelated cord blood transplantation after homogenous reduced-intensity conditioning in adults with hematological malignancy: impact of HLA disparities on outcomes. A French multicentre study on behalf of the SFGM-TC and Eurocord

Author

Rio, B., Furst, A., Renaud, M., Legrand, F., Tabrizi, R., Uzunov, M., Lapusan, S., Didier Blaise, Deconinck, E., Bourhis, H., Fouillard, L., Bulabois, C., Ceballos, P., Maury, S., Chevalier, P., Mohty, M., Francois, S., Huynh, A., Michallet, M., Sirvent, A., Dhedin, N., Contentin, N., Buzyn, A., Guyotat, D., Fagot, T., Yakoub-Agha, I., Gluckman, E., Ionescu, I., Milpied, N., and Rocha, V.

44. Outcomes of hematopoietic stem cell transplant for extranodal natural killer/T-cell lymphoma, nasal type: A study from the Societe Francophone de Greffe de Moelle et de Therapie cellulaire

Author

Philippe, L., Jaccard, A., Puyraveau, M., Courone, L., Sandy, A., Bachy, E., Banos, A., Bergerat, J-P, Berthou, C., Didier Blaise, Bourhis, J-H, Bulabois, C-E, Cahn, J-Y, Sylvain, C., Chevalier, P., Cornillon, J., Devidas, A., Drenoub, B., Faucher, C., Feugier, P., Francois, S., Gyan, E., Glaisner, S., Guillerm, G., Guyotat, D., Haoun, C., Huynh, A., Bay, J-O, Malfuson, J-V, Labussiere-Wallet, H., Leblond, V., Lengay, S., Lioure, B., Michallet, M., Milpied, N., Mohty, M., Moreau, P., Nguyenquoc, S., Ojeda-Uribem, M., Plantier, I., Rousselot, P., Rubio, M-T, Fontbrune, F. Sicre, Sirvent, N., Socie, G., Tabrizi, R., Revel, T., Thieblemont, C., Turlure, P., Yakoubagha, I., La Tour, R. Peffault, and Hermine, O.

46. Therapeutic management of patients relapsing after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome: a large-scale study on behalf of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

Author

Guieze, R., Damaj, G., Robin, M., Mohty, M., Michallet, M., Tabrizi, R., Beguin, Y., Didier Blaise, Roosweil, D., Bulabois, C. -E, Legrand, F., Huynh, A., Cornillon, J., Contentin, N., Suarez, F., Lioure, B., Maillard, N., Clement, L., Guillerm, G., Rubio, M. -T, Garnier, F., and Yakoub-Agha, I.

47. EFFECT OF IMMUNOMODULATION FOR PERIPHERAL T-CELL LYMPHOMA IN RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT: A SFGM-TC STUDY ON 64 PATIENTS

Author

Mamez, A. C., Levy, V., Chevallier, P., Vigouroux, S., Xhaard, A., Contentin, N., Mohty, M., Ibrahim Yakoub-Agha, Bulabois, C. E., Deconink, E., Lamy, T., Huynh, A., Fegueux, N., Turlure, P., Maury, S., Beguin, Y., Bourhis, J. H., Bilger, K., Bay, J. O., Guillerm, G., Suarez, F., Maillard, N., Rialland, F., Jubert, C., and Quoc, S. N.

49. Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT

Author

Giorgia Battipaglia, Jacques-Emmanuel Galimard, Myriam Labopin, Anna Maria Raiola, Didier Blaise, Annalisa Ruggeri, Yener Koc, Zafer Gülbas, Antonin Vitek, Simona Sica, Jose Luiz Diez-Martin, Luca Castagna, Benedetto Bruno, Montserrat Rovira, Ivan Moiseev, Massimo Martino, Giovanni Grillo, Mercedes Colorado Araujo, Claude Eric Bulabois, Stéphanie Nguyen, Gerard Socié, Mutlu Arat, Jiri Pavlu, Johanna Tischer, Hans Martin, Lucia Lopez Corral, Goda Choi, Edouard Forcade, Andrew McDonald, Fabrizio Pane, Ali Bazarbachi, Fabio Ciceri, Arnon Nagler, Mohamad Mohty, Battipaglia, G., Galimard, J. -E., Labopin, M., Raiola, A. M., Blaise, D., Ruggeri, A., Koc, Y., Gulbas, Z., Vitek, A., Sica, S., Diez-Martin, J. L., Castagna, L., Bruno, B., Rovira, M., Moiseev, I., Martino, M., Grillo, G., Araujo, M. C., Bulabois, C. E., Nguyen, S., Socie, G., Arat, M., Pavlu, J., Tischer, J., Martin, H., Corral, L. L., Choi, G., Forcade, E., Mcdonald, A., Pane, F., Bazarbachi, A., Ciceri, F., Nagler, A., Mohty, M., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Cyclophosphamide, Humans, Retrospective Studies, Transplantation Conditioning, Transplantation, Haploidentical, Unrelated Donors, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Myeloid, endocrine system, Transplantation, Leukemia, Leukemia, Myeloid, Acute/therapy, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hematology, Acute, Haploidentical, Cyclophosphamide/pharmacology, hemic and lymphatic diseases, Acute/therapy
Abstract

International audience; Whether to choose Haploidentical (Haplo) or one-antigen mismatched unrelated donor (1Ag-MMUD) hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PTCy) remains an unanswered question. We compared PTCy- Haplo-HCT to PTCy-1Ag-MMUD-HCT for acute myeloid leukemia (AML) in complete remission (three groups: 1Ag-MMUD using peripheral blood (1Ag-MMUD-PB; n = 155); Haplo using bone marrow (Haplo-BM; n = 647) or peripheral blood (Haplo-PB; n = 949)). Haplo-BM and Haplo-PB had a higher non-relapse mortality (NRM) compared to 1Ag-MMUD-PB (HR 2.28, 95% CI 1.23-4.24, p

Published
2022
Full Text
View/download PDF

50. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

Author

Gwendolyn Van Gorkom, Montserrat Rovira, Edouard Forcade, Myriam Labopin, Eolia Brissot, Annalisa Ruggeri, Alexandros Spyridonidis, Eric Deconinck, Martin Mistrik, Jan J. Cornelissen, Claude Eric Bulabois, Ian Moiseev, Ellen Meijer, Stephan Mielke, Laimonas Griskevicius, Sebastian Giebel, Didier Blaise, Riitta Niittyvuopio, Bipin N. Savani, Fabio Ciceri, Arnon Nagler, Jaime Sanz, Mohamad Mohty, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hematology, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CEREST-TC [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Pavlov First Saint Petersburg State Medical University [St. Petersburg], Erasmus University Medical Center [Rotterdam] (Erasmus MC), VU University Medical Center [Amsterdam], Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], University of Barcelona, IRCCS Ospedale San Raffaele [Milan, Italy], Universita Vita Salute San Raffaele = Vita-Salute San Raffaele University [Milan, Italie] (UniSR), Vilnius University [Vilnius], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Comenius University in Bratislava, University Hospital of Würzburg, Centre Hospitalier Universitaire [Grenoble] (CHU), Hôpital JeanMinjoz, Universitat de València (UV), General University Hospital of Patras, Vanderbilt University Medical Center [Nashville], Vanderbilt University [Nashville], Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Gestionnaire, Hal Sorbonne Université, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), HUS Comprehensive Cancer Center, Clinicum, Department of Oncology, Brissot, E., Labopin, M., Moiseev, I., Cornelissen, J. J., Meijer, E., Van Gorkom, G., Rovira, M., Ciceri, F., Griskevicius, L., Blaise, D., Forcade, E., Mistrik, M., Mielke, S., Bulabois, C. E., Niittyvuopio, R., Deconinck, E., Ruggeri, A., Sanz, J., Spyridonidis, A., Savani, B., Giebel, S., Nagler, A., Mohty, M., RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Hematologie (9), CCA - Cancer Treatment and quality of life, and CHU Saint-Antoine [AP-HP]

Subjects
Oncology, Male, Cancer Research, BLOOD, [SDV]Life Sciences [q-bio], MULTICENTER, Graft vs Host Disease, Kaplan-Meier Estimate, HEMATOLOGICAL MALIGNANCIES, PROPHYLAXIS, 0302 clinical medicine, antithymocyte globulin, prevention, Recurrence, immune system diseases, Cause of Death, hemic and lymphatic diseases, Antineoplastic Combined Chemotherapy Protocols, skin allograft tolerance, Medicine, Cumulative incidence, ComputingMilieux_MISCELLANEOUS, free survival, Hematology, Incidence (epidemiology), Incidence, Graft Survival, Remission Induction, Hematopoietic Stem Cell Transplantation, Myeloid leukemia, lcsh:Diseases of the blood and blood-forming organs, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Allografts, Combined Modality Therapy, 3. Good health, [SDV] Life Sciences [q-bio], Leukemia, Myeloid, Acute, surgical procedures, operative, 030220 oncology & carcinogenesis, Histocompatibility, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Post-transplant cyclophosphamide, Unrelated Donors, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, Cyclophosphamide, Adolescent, post-transplant cyclophosphamide, 3122 Cancers, matched unrelated donor, Human leukocyte antigen, acute myeloid leukemia, open-label, lcsh:RC254-282, Disease-Free Survival, MECHANISMS, versus-host-disease, 03 medical and health sciences, Young Adult, Internal medicine, Humans, Matched unrelated donor, Propensity Score, Molecular Biology, Aged, Antilymphocyte Serum, Retrospective Studies, Acute myeloid leukemia, business.industry, lcsh:RC633-647.5, Research, Transplantation, Propensity score matching, Antithymocyte globulin, business, 030215 immunology
Abstract

International audience; Full text linksfull-text provider logoActionsFavoritesSharePage navigation Title & authors Abstract Conflict of interest statement Figures References Related information LinkOut - more resourcesJ Hematol Oncol. 2020 Jul 3;13(1):87.doi: 10.1186/s13045-020-00923-0.Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donorsEolia Brissot 1 2 , Myriam Labopin 3 , Ian Moiseev 4 , J J Cornelissen 5 , Ellen Meijer 6 , Gwendolyn Van Gorkom 7 , Montserrat Rovira 8 , Fabio Ciceri 9 10 , Laimonas Griskevicius 11 , Didier Blaise 12 , Edouard Forcade 13 , Martin Mistrik 14 , Stephan Mielke 15 , Claude Eric Bulabois 16 , Riitta Niittyvuopio 17 , Eric Deconinck 18 , Annalisa Ruggeri 9 10 , Jaime Sanz 19 20 , Alexandros Spyridonidis 21 , Bipin Savani 22 , Sebastian Giebel 23 , Arnon Nagler 24 , Mohamad Mohty 25 26Affiliations PMID: 32620146 PMCID: PMC7333262 DOI: 10.1186/s13045-020-00923-0 Free PMC articleAbstractBackground: Graft-versus-host disease (GVHD) remains a major contributor to mortality and morbidity after allogeneic stem-cell transplantation (allo-HSCT). The updated recommendations suggest that rabbit antithymocyte globulin or anti-T-lymphocyte globulin (ATG) should be used for GVHD prophylaxis in patients undergoing matched-unrelated donor (MUD) allo-HSCT. More recently, using post-transplant cyclophosphamide (PTCY) in the haploidentical setting has resulted in low incidences of both acute (aGVHD) and chronic GVHD (cGVHD). Therefore, the aim of our study was to compare GVHD prophylaxis using either PTCY or ATG in patients with acute myeloid leukemia (AML) who underwent allo-HSCT in first remission (CR1) from a 10/10 HLA-MUD.Methods: Overall, 174 and 1452 patients from the EBMT registry receiving PTCY and ATG were included. Cumulative incidence of aGVHD and cGVHD, leukemia-free survival, overall survival, non-relapse mortality, cumulative incidence of relapse, and refined GVHD-free, relapse-free survival were compared between the 2 groups. Propensity score matching was also performed in order to confirm the results of the main analysis RESULTS: No statistical difference between the PTCY and ATG groups was observed for the incidence of grade II-IV aGVHD. The same held true for the incidence of cGVHD and for extensive cGVHD. In univariate and multivariate analyses, no statistical differences were observed for all other transplant outcomes. These results were also confirmed using matched-pair analysis.Conclusion: These results highlight that, in the10/10 HLA-MUD setting, the use of PTCY for GVHD prophylaxis may provide similar outcomes to those obtained with ATG in patients with AML in CR1.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results